Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS. / Talbot, J.; Højsgaard Chow, H.; Holm Hansen, R.; von Essen, M. Rode; Sellebjerg, F.

I: Journal of Neuroimmunology, Bind 361, 577756, 2021.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Talbot, J, Højsgaard Chow, H, Holm Hansen, R, von Essen, MR & Sellebjerg, F 2021, 'Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS', Journal of Neuroimmunology, bind 361, 577756. https://doi.org/10.1016/j.jneuroim.2021.577756

APA

Talbot, J., Højsgaard Chow, H., Holm Hansen, R., von Essen, M. R., & Sellebjerg, F. (2021). Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS. Journal of Neuroimmunology, 361, [577756]. https://doi.org/10.1016/j.jneuroim.2021.577756

Vancouver

Talbot J, Højsgaard Chow H, Holm Hansen R, von Essen MR, Sellebjerg F. Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS. Journal of Neuroimmunology. 2021;361. 577756. https://doi.org/10.1016/j.jneuroim.2021.577756

Author

Talbot, J. ; Højsgaard Chow, H. ; Holm Hansen, R. ; von Essen, M. Rode ; Sellebjerg, F. / Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS. I: Journal of Neuroimmunology. 2021 ; Bind 361.

Bibtex

@article{a353b8e031684970aa529929f74737ac,
title = "Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS",
abstract = "Dimethyl fumarate is an efficient therapy used widely in patients with relapsing-remitting multiple sclerosis (RRMS). However, lacking effect of treatment has recently been reported in patients with primary progressive MS (PPMS) (H{\o}jsgaard Chow et al., 2021). In order to further analyze the immunological treatment response we investigated the systemic and intrathecal immunological effects of dimethyl fumarate (DMF) treatment in 50 patients with PPMS who participated in a 48-week randomized controlled trial with dimethyl fumarate vs placebo. We found substantial systemic immunomodulatory effects of DMF treatment comparable with those observed in patients with RRMS. However, intrathecal effects were limited and restricted to CD4+ T cells presumably resulting in higher concentrations of intrathecal IL-7.",
keywords = "Cerebrospinal fluid immunology, Dimethyl fumarate, Flow cytometry, Primary progressive multiple sclerosis",
author = "J. Talbot and {H{\o}jsgaard Chow}, H. and {Holm Hansen}, R. and {von Essen}, {M. Rode} and F. Sellebjerg",
note = "Publisher Copyright: {\textcopyright} 2021 The Authors",
year = "2021",
doi = "10.1016/j.jneuroim.2021.577756",
language = "English",
volume = "361",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS

AU - Talbot, J.

AU - Højsgaard Chow, H.

AU - Holm Hansen, R.

AU - von Essen, M. Rode

AU - Sellebjerg, F.

N1 - Publisher Copyright: © 2021 The Authors

PY - 2021

Y1 - 2021

N2 - Dimethyl fumarate is an efficient therapy used widely in patients with relapsing-remitting multiple sclerosis (RRMS). However, lacking effect of treatment has recently been reported in patients with primary progressive MS (PPMS) (Højsgaard Chow et al., 2021). In order to further analyze the immunological treatment response we investigated the systemic and intrathecal immunological effects of dimethyl fumarate (DMF) treatment in 50 patients with PPMS who participated in a 48-week randomized controlled trial with dimethyl fumarate vs placebo. We found substantial systemic immunomodulatory effects of DMF treatment comparable with those observed in patients with RRMS. However, intrathecal effects were limited and restricted to CD4+ T cells presumably resulting in higher concentrations of intrathecal IL-7.

AB - Dimethyl fumarate is an efficient therapy used widely in patients with relapsing-remitting multiple sclerosis (RRMS). However, lacking effect of treatment has recently been reported in patients with primary progressive MS (PPMS) (Højsgaard Chow et al., 2021). In order to further analyze the immunological treatment response we investigated the systemic and intrathecal immunological effects of dimethyl fumarate (DMF) treatment in 50 patients with PPMS who participated in a 48-week randomized controlled trial with dimethyl fumarate vs placebo. We found substantial systemic immunomodulatory effects of DMF treatment comparable with those observed in patients with RRMS. However, intrathecal effects were limited and restricted to CD4+ T cells presumably resulting in higher concentrations of intrathecal IL-7.

KW - Cerebrospinal fluid immunology

KW - Dimethyl fumarate

KW - Flow cytometry

KW - Primary progressive multiple sclerosis

U2 - 10.1016/j.jneuroim.2021.577756

DO - 10.1016/j.jneuroim.2021.577756

M3 - Journal article

C2 - 34739914

AN - SCOPUS:85118344331

VL - 361

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

M1 - 577756

ER -

ID: 284703184